Sartorius Stedim BiotechSDMHF +2.46%80 FCF Margin % is 16.24% as of Mar. 2026, which is 63% above its 10-year median of 9.96. GuruFocus rates SDMHF with a GF Score™ of 80/100 and a GF Value™ of $239.66 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks better than 78.65% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (SDMHF) has a FCF Margin % of 16.24% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sartorius Stedim Biotech and its competitors. This is 63% above median its historical median of 9.96. Over the past decade, Sartorius Stedim Biotech's FCF Margin % has ranged from 4.19 to 17.10. According to the industry distribution chart, Sartorius Stedim Biotech ranks #174 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 21.3%.
Is Sartorius Stedim Biotech's FCF Margin % too high?
Sartorius Stedim Biotech's current FCF Margin % of 16.24% is 63% above median its 10-year median of 9.96. Over the past 10 years, this metric has ranged from a low of 4.19 to a high of 17.10. Based on the distribution chart, Sartorius Stedim Biotech ranks #174 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sartorius Stedim Biotech has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's FCF Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #174 out of 815 companies for FCF Margin %. This places Sartorius Stedim Biotech in the top 21% of its industry — outperforming the majority of peers. Historically, Sartorius Stedim Biotech's own FCF Margin % has ranged from 4.19 to 17.10 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current FCF Margin % is 16.24%, which is 63% above median its own 10-year median of 9.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (SDMHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $239.66, compared to a current price of $190.88 — trading 20.4% below its estimated fair value. The current FCF Margin % is 16.24%, which is 63% above median its 10-year median of 9.96. Sartorius Stedim Biotech's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Sartorius Stedim Biotech (SDMHF), the current FCF Margin % is 16.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (SDMHF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of $190.88 is trading 20.4% below its estimated GF Value™ of $239.66.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for SDMHF:
FCF Margin %: 16.24% (63% above median its 10-year median of 9.96)
GF Value™: $239.66 vs. price of $190.88 (20.4% below fair value)
No single metric tells the full story. See the SDMHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
80GF Score
Get the complete analysis for SDMHF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SDMHF has been successfully added to your 
